Form 4: Cellectar Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Frederick W. Driscoll, a director of Cellectar Biosciences, Inc., was granted stock options to purchase 60,000 shares of common stock on February 14, 2025.
Summary
- On February 14, 2025, Frederick W. Driscoll, a director of Cellectar Biosciences, Inc., acquired stock options.
- These options allow him to purchase 60,000 shares of Cellectar Biosciences' common stock at an exercise price of $0.29 per share.
- The options vest fully on February 14, 2026, contingent upon Driscoll's continued service with the company.
- The options expire on February 14, 2035.
Sentiment
Score: 7
Explanation: The granting of stock options to a director is generally viewed positively as it aligns their interests with shareholders. The vesting period suggests a commitment to the company's long-term success.
Positives
- The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
- The vesting period of one year suggests a commitment from the director to remain with the company.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and directors, aligning their interests with those of shareholders and encouraging long-term value creation.
Comparison to Industry Standards
- Stock option grants to directors are a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
- The vesting schedule of one year is fairly standard, aligning with typical performance evaluation cycles.
- The exercise price is set at $0.29, which may be at or near the current market price of the stock at the time of the grant.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the transaction: Frederick Driscoll acquired stock options. |
| 02/14/2026 | Vesting date for the stock options, contingent upon continued service. |
| 02/14/2035 | Expiration date of the stock options. |
| 02/18/2025 | Date of the form filing. |
Keywords
stock options, director, Cellectar Biosciences, CLRB, Form 4, beneficial ownership, Frederick Driscoll
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.